For the quarter ending 2026-03-31, MYGN made $200,400K in revenue. -$34,100K in net income. Net profit margin of -17.02%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 200,400 | 209,800 | 205,700 | 213,100 |
| Cost of revenue | 62,800 | 63,000 | 61,900 | 61,300 |
| Gross profit | 137,600 | 146,800 | 143,800 | 151,800 |
| Research and development expense | 27,100 | 25,500 | 28,200 | 25,600 |
| Sales and marketing expense | 73,600 | 68,700 | 71,000 | 71,900 |
| General and administrative expense | 62,200 | 55,600 | 67,900 | 66,800 |
| Legal settlements | - | 0* | - | - |
| Goodwill and long-lived asset impairment charges | 5,400 | 2,700* | 0 | 316,700 |
| Total operating expenses | 168,300 | 152,500 | 167,100 | 481,000 |
| Operating loss | -30,700 | -5,700 | -23,300 | -329,200 |
| Interest income | 700 | 800 | 500 | 200 |
| Interest expense | 4,100 | 4,400 | 3,800 | 1,500 |
| Other | 0 | 400 | 400 | -100 |
| Total other expense, net | -3,400 | -3,200 | -2,900 | -1,400 |
| Loss before income tax | -34,100 | -8,900 | -26,200 | -330,600 |
| Income tax benefit | 0 | -1,000 | 1,200 | -100 |
| Net loss | -34,100 | -7,900 | -27,400 | -330,500 |
| Basic EPS | -0.36 | -0.085 | -0.29 | -3.57 |
| Diluted EPS | -0.36 | -0.085 | -0.29 | -3.57 |
| Basic Average Shares | 93,700,000 | 93,400,000 | 93,100,000 | 92,500,000 |
| Diluted Average Shares | 93,700,000 | 93,400,000 | 93,100,000 | 92,500,000 |
MYRIAD GENETICS INC (MYGN)
MYRIAD GENETICS INC (MYGN)